CD274 and cancer: It has recently been shown that both metformin and 2DG can partially abrogate the ability of cancer cells to suppress the functionality of T cells through the PD-1/PD-L1 axis, and that metformin can partially improve response to immune checkpoint inhibitors (ICI) in cancer therapy [42,43].